Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.
DNLI - Denali Therapeutics Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$34.60
DETAILS
HIGH:
$41.00
LOW:
$26.00
MEDIAN:
$35.00
CONSENSUS:
$34.60
UPSIDE:
48.56%
Stock News
Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that co-founder and Chief Executive Officer Ryan Watts, Ph.D., will deliver the opening plenary address, titled “Accelerating the Discovery and Development of Medicines for Neurodegeneration,” at the Alzheimer's Association International Conference® (AAIC), taking place July 12-15 in London. Dr. Watts will discuss recent scientific advances and future opportunities including new insights in the biology of disease, the use of biomarkers for diagnosis and assessment of treatment effect, and the potential for therapeutics to cross the blood-brain barrier for enhanced delivery to the brain.
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.
Denali to Sell Priority Review Voucher for $195M Cash Boost
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
SOUTH SAN FRANCISCO, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. The U.S. Food and Drug Administration (FDA) awarded the PRV to Denali following accelerated approval of the enzyme replacement therapy AVLAYAH™ (tividenofusp alfa-eknm) for the treatment of Hunter syndrome (mucopolysaccharidosis type II; MPS II) in March 2026. AVLAYAH is the first FDA-approved medicine in an emerging class of biotherapeutics designed to cross the blood-brain barrier via transferrin receptor (TfR)-mediated transport.
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
Denali Therapeutics (DNLI) maintains a "Strong Buy" rating following FDA Accelerated Approval of AVLAYAH for Hunter Syndrome and robust pipeline momentum. Company's DNL593 for FTD-GRN is differentiated by restoring both extracellular and lysosomal PGRN; phase 1/2 data readout expected by end of 2026. AVLAYAH's full approval depends on confirmatory COMPASS study results; commercial performance remains unproven post-April 2026 launch.
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
Denali Therapeutics NASDAQ: DNLI is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24 accelerated approval for Hunter syndrome, Chief Operating Officer and Chief Financial Officer Alexander Schuth said at a Bank of America Securities conference.
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2026, and provided business highlights, including the recent U.S. Food and Drug Administration (FDA) approval of AVLAYAH™ (tividenofusp alfa-eknm).
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval
This biotech company develops therapies for neurodegenerative and rare diseases, supported by clinical assets and pharma collaborations.
Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform
Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease company with FDA approval of AVLAYAH for Hunter syndrome. DNLI's TransportVehicle technology enables delivery of biologics across the blood-brain barrier, providing significant differentiation and commercial potential in neurodegenerative and lysosomal storage diseases. With $1.17 billion in pro-forma liquidity and a focused initial launch, DNLI is positioned for 2.8 years of runway, reducing near-term capital risk.
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
DNLI secures FDA nod for Avlayah, a first-in-decades Hunter syndrome therapy, but pipeline risks and Takedas exit complicate the outlook.
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
DNLI's shares decline after Takeda exits DNL593 partnership, leaving Denali to fully control and fund the therapy as it advances studies and plans 2026 data release.
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Takeda on Friday notified Denali Therapeutics regarding the termination of their collaboration agreement to co-develop DNL593, a progranulin replacement therapy for frontotemporal dementia.
Capricorn Fund Managers Ltd Acquires New Position in Denali Therapeutics Inc. $DNLI
Capricorn Fund Managers Ltd acquired a new stake in Denali Therapeutics Inc. (NASDAQ: DNLI) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 62,197 shares of the company's stock, valued at approximately $1,027,000. Other institutional investors and hedge funds
SG Americas Securities LLC Increases Stock Position in Denali Therapeutics Inc. $DNLI
SG Americas Securities LLC boosted its holdings in Denali Therapeutics Inc. (NASDAQ: DNLI) by 291.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 149,592 shares of the company's stock after buying an additional 111,391 shares during the period. SG Americas
Price Targets
Denali Therapeutics price target raised to $26 from $20 at Wedbush
$26.00
(was $25.33)
Laura Chico
·
Wedbush
Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
$41.00
(was $23.76)
Paul Mattels
·
Stifel Nicolaus
Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley
$35.00
(was $18.64)
Morgan Stanley
Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank
$31.00
(was $18.61)
Deutsche Bank
Denali Therapeutics price target lowered to $23 from $25 at Wedbush
$23.00
(was $20.11)
Laura Chico
·
Wedbush
Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank
$35.00
(was $19.74)
Deutsche Bank
Jefferies Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
$40.00
(was $21.00)
Andrew Tsai
·
Jefferies
Denali Therapeutics price target raised to $40 from $32 at Morgan Stanley
$40.00
(was $16.95)
Sean Laaman
·
Morgan Stanley
UBS Assumes Denali Therapeutics Inc. (DNLI) at Buy
$25.00
(was $17.21)
Michael Yee
·
UBS
Denali Therapeutics price target lowered to $30 from $31 at Wedbush
$30.00
(was $17.61)
Laura Chico
·
Wedbush
Denali Therapeutics price target raised to $31 from $30 at Wedbush
$31.00
(was $20.11)
Laura Chico
·
Wedbush
Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
$37.00
(was $17.67)
Paul Mattels
·
Stifel Nicolaus
Denali Therapeutics price target lowered to $32 from $35 at BTIG
$32.00
(was $21.18)
Thomas Shrader
·
BTIG
Denali Therapeutics Inc. (DNLI) PT Raised to $45 at Jefferies
$45.00
(was $27.05)
Michael Yee
·
Jefferies
BTIG Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
$35.00
(was $28.00)
Thomas Shrader
·
BTIG
Denali Therapeutics price target raised to $29 from $25 at BofA
$29.00
(was $25.12)
Tazeen Ahmad
·
Bank of America Securities
B.Riley Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
$33.00
(was $25.12)
Marank Mamtani
·
B.Riley Financial
Goldman Sachs Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
$46.00
(was $25.12)
Salveen Richter
·
Goldman Sachs
Stifel Reiterates Hold Rating on Denali Therapeutics Inc. (DNLI)
$22.00
(was $25.12)
Paul Mattels
·
Stifel Nicolaus
Denali Therapeutics Inc. (DNLI) PT Raised to $112 at Goldman Sachs
$112.00
(was $52.93)
Salveen Richter
·
Goldman Sachs